Gilead Buys PepStar Inflammation Program for $1.275B
The deal gives Gilead a new oral drug candidate for inflammatory bowel disease as it shifts its pipeline strategy.
Updated on Oct. 22, 2026 in Healthcare
Live Poll
Do you believe the acquisition of smaller drug programs by large pharmaceutical companies benefits patients?
Gilead Sciences has agreed to purchase PepStar Therapeutics’ oral inflammation drug program for $1.275 billion in cash. The acquisition centers on the experimental drug HCXT-2001, which is currently undergoing early-stage clinical testing for inflammatory bowel disease.
Why it matters
This move allows Gilead Sciences to expand its pipeline into the competitive inflammatory bowel disease market by securing a novel oral therapy targeting the IL-23 pathway. For operators in the sector, it highlights the continued high valuation for early-stage pipeline assets targeting major chronic conditions.
Gilead Sciences finalized a $1.275 billion cash acquisition of PepStar Therapeutics’ oral inflammation program. The deal centers on the development of HCXT-2001, an early-stage candidate for inflammatory bowel disease.
The players
Gilead Sciences
A research-based biopharmaceutical firm focused on developing and commercializing medicines for life-threatening diseases.
PepStar Therapeutics
A clinical-stage biotechnology company focused on the development of novel small-molecule drugs for inflammatory conditions.
The details
Gilead Sciences is acquiring the oral inflammation program to gain control over HCXT-2001, a drug candidate that inhibits the IL-23 pathway. By pursuing an oral delivery method for this pathway, Gilead aims to provide a more patient-accessible treatment profile compared to existing injectable biological therapies. The program is still in its early clinical development stages, meaning the company faces significant regulatory and trial hurdles before a potential commercial launch.
Timeline
October 22, 2026: Gilead Sciences announced the cash acquisition of the PepStar Therapeutics drug program.
Market Landscape
This deal underscores a broader industry shift toward internalizing novel oral assets as companies look to de-risk against future pricing pressures. It follows a pattern of major firms acquiring early-stage technology to compete under the Inflation Reduction Act's Medicare drug-price negotiation provisions.
Operators in the pharmaceutical and biotech space should monitor Gilead's progression of the IL-23 pathway as a benchmark for oral-delivery efficacy. Future capital allocation for similar early-stage inflammation assets may tighten as investors compare these development costs against projected commercial viability.
The takeaway
The acquisition signifies the high strategic value placed on oral therapy candidates within the inflammatory bowel disease space. Biotech operators should track clinical progress for HCXT-2001 to gauge whether oral alternatives can effectively challenge incumbent injectable biologics.
Further reading
For more on industry consolidation, see the latest updates in Healthcare.
Live Poll
Do you believe the acquisition of smaller drug programs by large pharmaceutical companies benefits patients?
